Sponsor / CRO Zone
Multidisciplinary Clinical Trial Site in Poland
AidPort brings together experienced investigators, dedicated hospital facilities and diagnostic expertise in the Poznań area. We conduct clinical trials across multiple therapeutic areas.
79
Clinical trials opened
510
Patients randomized
Across all indications · 2024–2026



Therapeutic Areas
- 01
Oncology & Hematology
- 02
Cardiology
- 03
Neurology
- 04
Rheumatology
- 05
Women's Health
- 06
Metabolic Diseases & Diabetology
Our Investigators
Clinical Research Experience Across Therapeutic Areas
Meet the investigators featured in AidPort's published portfolio. Explore their therapeutic expertise and research track record, including experience gained before joining AidPort.

[01]
12
Named investigators
in the published portfolio
[02]
90
Listed study records
across 6 core portfolios
[03]
~1,426
Reported randomizations
across those records
[04]
Since 2012
Earliest study start
in the published track record
Therapeutic Areas
Portfolio
[01]
Oncology
- Piotr TomczakMD, PhD
- Renata SzoszkiewiczMD, PhD
Indications
SOLID TUMORS: LUNG CANCER, COLORECTAL CANCER, GASTRIC CANCER, BREAST CANCER (TNBC / HER2+ / HR+), UROTHELIAL CANCER, KIDNEY CANCER, PROSTATE CANCER, MELANOMA, OVARIAN CANCER, ENDOMETRIAL CANCER
Show data
| Indication | Phase | Recruitment period | Randomization |
|---|---|---|---|
| mCRC - 1st line | 1 | 2021-2022 | 4 |
| Kidney Cancer, Melanoma | 1 | 2020-2021 | 32 |
| Melanoma | 3 | 2022-current | 2 |
| TNBC | 2 | 2018-2019 | 9 |
| BC - HR+/HER2- | 3 | 2021-2022 | 4 |
| UROTHELIAL CANCER | 2 | 2020-2022 | 12 |
| UROTHELIAL CANCER - neoadjuvant trament + radical cystectomy | 3 | 2023-current | 4 |
| SOLID TUMORS (basket) | 1 | 2022-2023 | 5 |
| mCRC with PI3K mut | 1 | 2020-2022 | 3 |
| Prostate Cancer | 1 | 2021-2022 | 6 |
| TNBC | 3 | 2022-2022 | 5 |
[02]
Hematology
- Michal KwiatekMD, PhD
- Lukasz PruchniewskiMD, PhD
- Maciej KazmierczakMD, PhD
Indications
NHL-B, NHL-T, CLL, MDS, AML, MPN (MF, PV, ET, CML), ITP, MM, RARE DISEASE
Show data
| Indication | Phase | Recruitment period | Randomization |
|---|---|---|---|
| AML | 2 | 2017-2019 | 26 |
| ITP. | 2 | 2017-2018 | 16 |
| ITP. | 3 | 2021-2021 | 10 |
| MF after JAK-I | 3 | 2021 - aktualnie | 6 |
| CLL | 3 | 2019-2020 | 49 |
| CLL | 3 | 2022-2022 | 14 |
| 1 L CLL / RR CLL | 2 | 2022 - 2023 | 18 |
| R/R DLBCL | 3 | 2021 - aktualnie | 14 |
| INDOLENT NHL-B | 1 | 2021-2022 | 9 |
| NHL-B | 1 | 2021-2022 | 5 |
| NHL-B | 1 | 2021-2022 | 17 |
| 1 L CLL / RR CLL | 3 | 2022 - aktualnie | 12 |
| ITP. | 2 | 2022-2022 | 9 |
| R/R FL | 3 | 2022 - aktualnie | 6 |
| R/R FL | 2 | 2020-2021 | 9 |
| R/R NHL-B | 1 | 2023 - aktualnie | 4 |
| PNH | 3 | 2021-2021 | 2 |
| PNH | 3 | 2021-2021 | 2 |
| 1 L DLBCL | 2 | 2023 - 2023 | 4 |
| R/R NHL-B | 1 | 2022-2022 | 9 |
| R/R MCL | 3 | 2022 - aktualnie | 4 |
[03]
Women's Health
- Krzysztof SzymanowskiMD, PhD
Indications
FIBROIDS, ENDOMETRIOSIS, HOT FLASHES, OSTEOPOROSIS
Show data
| Indication | Phase | Recruitment period | Randomization |
|---|---|---|---|
| Fibroids | 3 | 2018-2019 | 10 |
| Endometriosis | 3 | 2019-2020 | 32 |
| Endometriosis | 2 | 2021-2022 | 17 |
| Osteoporosis | 3 | 2020-2020 | 56 |
| Osteoporosis | 3 | 2022-2022 | 26 |
| Hot Flashes | 3 | 2020-2021 | 104 |
| Hot Flashes | 3 | 2021-2021 | 12 |
| Hot Flashes | 2 | 2021-2021 | 24 |
| Hot flashes due to endocrine adjuvant breast cancer treatment | 3 | 2022-aktualnie | 9 |
[04]
Cardiology
- Michał LewandowskiMD, PhD
- Anna KomosaMD, PhD
- Magdalena ŁanochaMD, PhD
Indications
Show data
| Indication | Phase | Recruitment period | Randomization |
|---|---|---|---|
| PULMONARY ARTERIAL HYPERTENSION | 2 | 2024 - 2025 | 1 |
| PULMONARY ARTERIAL HYPERTENSION (PAH) | 2B/3 | 2023-2024 | 1 |
| ATHEROSCLEROTIC CARDIOVASCULAR DISEASE | 3 | 2022 – ongoing | 14 |
| CHRONIC HEART FAILURE | 1 | 2023 – 2024 | 3 |
| HEART FAILURE | 2 | 2022 – 2024 | 3 |
| HEART FAILURE AFTER MYOCARDIAL INFARCTION | 2 | 2022 – 2024 | 10 |
| ATRIAL FIBRILLATION | 3 | 2019-2021 | 18 |
| ACUTE CORONARY SYNDROME | 3 | 2018-2021 | 12 |
| DYSLIPIDEMIA | 3 | 2016-2018 | 17 |
| ATRIAL FIBRILLATION | 3 | 2015-2017 | 18 |
| ISCHEMIC HEART DISEASE | 3 | 2016 – 2018 | 14 |
| ACUTE CORONARY SYNDROMES | 3 | 2013 - 2016 | 22 |
| ISCHEMIC HEART DISEASE | 3 | 2012 - 2014 | 6 |
| ISCHEMIC HEART DISEASE | 1 | 2019 – 2022 | 8 |
| ACUTE CORONARY SYNDROME | 2 | 2019 – 2021 | 14 |
| ACUTE CORONARY SYNDROME | 3 | 2017 - 2020 | 35 |
| ISCHEMIC HEART DISEASE | 2 | 2018 - 2019 | 8 |
| HEART FAILURE | 2 | 2018 – 2020 | 12 |
| HEART FAILURE | 2 | 2016 -2018 | 4 |
| ISCHEMIC HEART DISEASE | 2 | 2017 - 2019 | 8 |
| ISCHEMIC HEART DISEASE | 3 | 2018 - 2020 | 34 |
| ISCHEMIC HEART DISEASE | 3 | 2016 - 2020 | 8 |
| DYSLIPIDEMIA | 3 | 2017-2021 | 28 |
| ACUTE CORONARY SYNDROME | 3 | 2018 - 2020 | 10 |
| ISCHEMIC HEART DISEASE | 3 | 2019 - 2021 | 8 |
| ISCHEMIC HEART DISEASE | 3 | 2018 - 2020 | 12 |
| ACUTE CORONARY SYNDROME | 3 | 2018 - 2021 | 72 |
| DYSLIPIDEMIA | 2 | 2012 – 2016 | 12 |
| HEART FAILURE | 3 | 2013 - 2015 | 4 |
| HEART FAILURE | 3 | 2014 - 2018 | 36 |
| BIO DYSLIPIDEMIA | 1 | 2016 - 2019 | 68 |
[05]
Early Phases
Indications
Show data
| Indication | Phase | Recruitment period | Randomization |
|---|---|---|---|
| RHEUMATOLOGY: DISCOID LUPUS ERYTHEMATOSUS, SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS OR SYSTEMIC LUPUS ERYTHEMATOSUS | 1B | 2021 – ongoing | 1 |
| GASTROENTEROLOGY: PULMONARY CIRRHOSIS OF THE LIVER | 2B | 2024 - 2025 | 1 |
| DERMATOLOGY: MODERATE TO SEVERE ATOPIC DERMATITIS | 2B | 2024 – ongoing | 1 (SF) |
| RHEUMATOLOGY: SYSTEMIC LUPUS ERYTHEMATOSUS | FIRST IN HUMAN | 2024 - ongoing | |
| RHEUMATOLOGY: SYSTEMIC LUPUS ERYTHEMATOSUS | OPEN LABEL | 2021 - 2023 | 1 |
[06]
Neurology
- Karolina Piasecka – StryczyńskaMD, PhD
Indications
Show data
| Indication | Phase | Recruitment period | Randomization |
|---|---|---|---|
| CHRONIC MIGRAINE – CM-MOH | 4 | 2019 – 2022 | c. 60 – TOP RECRUITER IN THE WORLD |
| RELAPSING MS - MS200527_0082 - NATIONAL COORDINATOR | 3 | 2020 - 2024 | c. 60 – TOP RECRUITER IN THE WORLD |
| PPMS - GN41791 | 3 | 2021 – ONGOING | 9 |
| RELAPSING MS - GN42272 | 3 | 2022 – ONGOING | 30 |
| RR MULTIPLE SCLEROSIS - WA40404 - EASTERN EUROPE COORDINATOR | 3 | 2022 – ONGOING | 6 |
| RELAPSING MS - CLOU64C12301 | 3 | 2022 – ONGOING | 41 |
| MULTIPLE SCLEROSIS - BP42230 | 1 | 2023 – ONGOING | 7 |
| MYASTHENIA GRAVIS - VIB0551.P3.S1 | 3 | 2023 – ONGOING | 3 |
| RELAPSING MS - CTP53 | 1/3 | 2024 – ONGOING | 34 |
[07]
Rheumatology
- Magdalena SzyszkoMD, PhD
Indications
Show data
| Indication | Phase | Recruitment period | Randomization |
|---|---|---|---|
| SJOGREN'S SYNDROME - EUDRACT: 2021-005911-30 | 2 | 2023 | 5 |
| SJOGREN'S SYNDROME - EUCT: 2023-503915-14-00 | 2 | 2023 | 4 |
| SJOGREN'S SYNDROME NCT06747949 | 2 | 2023 - ONGOING | 3 |
| SJOGREN'S SYNDROME EUCT: 2024-516609-22-00 | 2 | 2025 - ONGOING | 3 |
| SJOGREN'S SYNDROME NCT06104124 | 2 | 2025 - ONGOING | 3 |
| SJOGREN'S SYNDROME NCT06312020 | 2 | 2024 - ONGOING | 3 |
| SJOGREN'S SYNDROME 417-201-00042 | 2 | 2025 | 1 |
| RHEUMATOID ARTHRITIS EUCT: 2023-506664-14-00 | 3 | 2024 - 2025 | 4 |
| PSORIATIC ARTHRITIS AND DISEASES ACCOMPANYING INTESTINAL DISORDERS EUCT: 2024-513111-27-00 | 3 | 2025 | 9 |
Our Team
Clinical Research Team
Experienced investigators work with dedicated research, pharmacy, patient service and administrative teams across therapeutic areas.
14
Clinical research coordinators
5
Research nurses
4
Clinical trial pharmacists

[01]
Physicians & Investigators
Medical expertise across therapeutic areas.
[02]
Clinical Research Coordinators
Study coordination and sponsor / CRO communication.
[03]
Qualified Research Nurses
Study visits, treatment administration and procedures.
[04]
Clinical Trial Pharmacists
Investigational product management and preparation.
[05]
Patient Service Office
Visit scheduling and support for patients.
[06]
Administrative Team
Contracting, financial administration and settlements.
GCP & Internal Training
GCP & Regular Internal Training
All team members have current GCP training and receive regular internal training in clinical research, site procedures and study requirements.
Specialist Education
Postgraduate Clinical Research Education
Most team members have completed postgraduate studies in clinical research, complementing their practical experience.
Our team combines clinical research experience with empathy and support throughout patients' visits and treatment.
Facility
Clinical Trial Facilities
Our purpose-built hospital supports outpatient study visits, investigational treatments and protocol-required procedures across therapeutic areas.
1,300 m²
Dedicated research infrastructure
10
Consultation rooms
10
Infusion stations
[01]
Outpatient & Procedure Facilities
Ten consultation rooms, four dedicated nursing rooms, a gynecology office and a procedure room support study visits, bone marrow biopsies and targeted tumor biopsies.
Patient rest area for visits involving serial PK/PD sampling
[02]
Onco-Hematology Ward
Ten infusion stations and two single rooms support treatment and observation. Infusion pumps, patient monitors and a patient alarm system support chemotherapy, immunotherapy and targeted therapies.
Dedicated treatment and observation facilities
[03]
On-Site Hospital Pharmacy
An on-site pharmacy supports investigational product storage, accountability and preparation, with dedicated cytotoxic preparation facilities and temperature-controlled storage.
In-house support for blinded and unblinded studies
[04]
Sponsor & CRO Monitoring Workspace
Dedicated rooms provide workspace for sponsor and CRO monitoring visits.
Tour the Hospital & Pharmacy

Video hosted on YouTube. Playing it lets YouTube (Google) process your data and set cookies.

Video hosted on YouTube. Playing it lets YouTube (Google) process your data and set cookies.
Dedicated Equipment
Clinical Trial Equipment & Safety Systems
Dedicated equipment supports treatment, patient assessments and sample processing. Temperature monitoring and backup power support continuity of research operations.

Continuous Temperature Monitoring
Continuous Temperature Monitoring
Central temperature records cover investigational product and study sample storage across the hospital.
30+
Temperature measurement points
24/7/365
Remote access to real-time temperature records
SMS alarm notifications
Alerts are sent to the centre director, principal investigator and chief pharmacist.
Backup Power
Continuity During Power Outages
A backup generator maintains hospital operation during mains power interruptions.
Emergency Readiness
Equipment for Acute Reactions
Emergency kits for the management of anaphylaxis and resuscitation equipment support the clinical team's response to acute reactions.

Clinical Trial Equipment
[01]
Treatment & Patient Assessment
- Infusion pumps and patient monitors
- ECG machines
- Ultrasound machine
- Bone densitometer
- Stadiometers and scales
- Satellite clocks for synchronized timing
[02]
Sample Processing & Storage
- Refrigerated centrifuges
- Laboratory incubators
- Deep-freeze storage
[03]
Investigational Product Handling
- Pharmaceutical refrigerators: 2–8°C
- Pharmaceutical freezers: −20°C and −80°C
- Two certified laminar flow hoods
- Dedicated cytotoxic drug preparation facilities
Equipment validation, certificates and technical documentation support study set-up and sponsor review.
Source Data / Medical Records
ALCOA+ Data Integrity & Monitoring
Electronic medical and pharmacy records support ALCOA+ principles through traceable entries, full audit trails and individual access permissions.
100%
Electronic medical records
Full audit trail
Timestamped entries and changes
Read-only
Controlled CRA access
Clinical Source Documentation
Study Activities Documented Electronically
Our hospital system records visits, procedures, treatments, infusions and observation stays, including administration timing and clinical observations.
A full audit trail records the creation of and changes to entries, with timestamps and attribution.
Pharmacy Documentation
Investigational Product Traceability
The system supports pharmacy operations, medicine preparation and management of investigational medicinal products (IMPs).
Pharmacy records support traceability of investigational product handling, preparation and dispensing.
Monitoring Facilities & Access
Dedicated Monitoring Rooms & CRA Access
Dedicated rooms support on-site review. Our team coordinates room availability, study documentation and access to site personnel.
[01]
On-Site Monitoring
Individual, read-only access to relevant electronic source records, within assigned permissions.
[02]
Remote Monitoring
Read-only remote access, subject to permissions and agreed study arrangements.
Quality Management
Clinical Trial Quality Management
Defined procedures, documented qualifications and clear responsibilities support quality in our daily clinical research operations.
SOPs
Procedures Grounded in Daily Practice
Key site processes follow SOPs that reflect our actual working practices and support daily quality control.
Available for review by sponsor and CRO representatives, auditors and inspectors.
Internal QMS
Documented Training & Qualifications
Our internal Quality Management System (QMS) records staff qualifications and generates training logs for GCP and internal training.
Training covers clinical research practice, site procedures and study requirements.
Clear Roles Across the Site
Our organizational structure defines individual responsibilities across four operational units, supporting study delivery, audits and inspections.
- 01Medical Team
- 02Clinical Research Coordination
- 03Hospital Pharmacy
- 04Administration
Contracting & Study Start-Up
Efficient Clinical Trial Contracting
Our legal and start-up teams coordinate clinical trial agreements and budgets with sponsors and CROs.
80
Executed Study Agreements
In 18 months
29
Working Days on Average
Contract and budget
Sponsor Templates Accepted
We work with sponsor-provided agreement templates.
Master Agreements
Framework agreements are in place with multiple sponsors.
Contracts Lead

Blanka Cybińska
Contact our team to discuss your study's contractual and budget requirements.
Diagnostic Capabilities
Diagnostic Capabilities for Clinical Trials
AidPort connects clinical trial delivery with histopathology, molecular testing and diagnostic imaging, supported by DIAGNOSTYKA's nationwide laboratory network.
[01 / Tissue]
Histopathology
10 working days
Target time from biopsy to result.
Histopathological assessment to support study screening and diagnostic decisions.
DIAGNOSTYKA+ Consilio
[02 / Molecular]
Molecular Diagnostics
NGS
NGS, FISH and PCR testing.
Molecular characterization for biomarker-driven study pathways.
Oncogene
[03 / Imaging]
Diagnostic Imaging
CT / MRI / PET-CT
Access to diagnostic imaging.
Imaging for screening, disease assessment and response evaluation.
DIAGNOSTYKA+ obrazowa
[04 / Diagnostyka]
Laboratory Diagnostics
~1,300
Specimen collection points across Poland.
Laboratory testing closer to home, subject to study-specific sampling arrangements.
DIAGNOSTYKA+
Diagnostic scope, turnaround targets and local sampling arrangements are agreed for each study.
DIAGNOSTYKA Group network: approximately 1,300 specimen collection points. Source: H1 2026 Management Report.
Company Presentation
Discover more about our facility capabilities and clinical trials. Click the icon below to download the full PDF portfolio.
Sponsor / CRO Contact
Contact Our Clinical Research Team
Discuss study feasibility, operations, start-up or partnerships with the right person at AidPort.
Send a Study Enquiry

Medical Feasibility
Michał Kwiatek
Medical Director

Study Operations
Joanna Lorenc
Director of Clinical Research

Start-Up & Settlements
Blanka Cybińska
CFO, Contract Manager

New Studies & Partnerships
Michał Zmysłowski
Growth & Development
Visit AidPort
AidPort Clinical Trial Hospitalul. Księdza Stanisława Kozierowskiego 24
60-185 Skórzewo, Poznań area, Poland
Hospital reception: +48 570 894 700
